Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of
chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are rare. The mean …

The treatment recommendations for chronic myelogenous leukemia (CML) are evolving
rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr …

Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML),
but some patients do not respond and many responses are not durable. To improve the …

This study investigated the feasibility of allogeneic (alloSCT) and autologous stem cell
transplantation (ASCT) as postconsolidation therapy for patients with myelodysplastic …

Abstract Interferon‐α (IFN‐α) alone or in combination with cytostatic drugs can induce major
and durable cytogenetic responses in about 20 to 25% of chronic myeloid leukemia (CML) …

BACKGROUND AND OBJECTIVE: Interferon-a (IFN) is increasingly being used as the drug
of choice in chronic myeloid leukemia patients. The main objectives of the study were to …

This chapter deals with the application of fluorescence in situ hybridization (FISH) to study
interphase nuclei from patients with chronic myeloid leukemia (CML). In our experience …

Small pilot studies of patients with CML have reported on encouraging response rates after
treatment with interferon-alpha (IFNα) in combination with low-dose cytosine arabinoside …

Newly diagnosed chronic myelogenous leukaemia (CML) patients (n= 65) were treated with
interferon (IFN)‐α2b (5× 106 IU/d sc) combined with monthly courses of cytarabine (20 mg/d …

A multicentre clinicopathological study was performed on 495 patients with chronic‐phase
Ph1+ chronic myelogenous leukaemia (CML) to determine bone marrow characteristics that …